Is mirtazapine appropriate for treating insomnia, and what is the recommended dosing regimen?

Mirtazapine for Sleep: Not a First-Line Option

Mirtazapine should not be used as a first-line treatment for primary insomnia, but may be considered as a third-line option when comorbid depression/anxiety exists or after failure of FDA-approved hypnotics. The most recent American Academy of Sleep Medicine (AASM) 2017 guideline does not include mirtazapine in its recommendations, and the 2008 AASM guideline explicitly states that mirtazapine is "not FDA approved for insomnia and their efficacy for this indication is not well established" 1.

Treatment Algorithm for Chronic Insomnia

First-Line: FDA-Approved Hypnotics

Start with short-intermediate acting benzodiazepine receptor agonists (BzRAs) or ramelteon 1:

• Zolpidem 10 mg (5 mg in elderly/debilitated)
• Eszopiclone 2-3 mg (1 mg in elderly/debilitated)
• Zaleplon 10 mg (5 mg in elderly/debilitated)
• Temazepam 15-30 mg (7.5 mg in elderly/debilitated)
• Ramelteon 8 mg (for sleep-onset insomnia)

The 2017 AASM guideline provides weak recommendations for these agents, while the 2020 VA/DoD guideline suggests low-dose doxepin (3-6 mg) or nonbenzodiazepine BzRAs for short courses 2, 3.

Second-Line: Alternative BzRAs

If initial agent fails, try a different BzRA based on symptom pattern 1:

• Sleep-onset insomnia: Zaleplon or ramelteon (very short half-life, minimal residual sedation)
• Sleep-maintenance insomnia: Eszopiclone or temazepam (longer half-life)

Third-Line: Sedating Antidepressants (Including Mirtazapine)

Only consider when 1:

1. Comorbid depression or anxiety exists
2. First and second-line agents have failed
3. Patient has history of substance abuse (prefer non-scheduled agents)

If using mirtazapine for insomnia:

• Dosing: The FDA label recommends 15 mg at bedtime as the starting dose for depression 4. However, off-label use for insomnia typically employs lower doses:
  • Ultra-low dose: 3.75 mg showed meaningful ISI improvement in 47% of veterans 5
  • Low dose: 7.5 mg improved total sleep time by 30 minutes and reduced awakenings by 35-40% in healthy volunteers 6
  • Standard low dose: 7.5 mg significantly reduced ISI scores in older adults with chronic insomnia (mean change -6.5 vs -2.9 for placebo) 7

Critical Evidence Gaps and Concerns

Lack of FDA Approval

Mirtazapine is not FDA-approved for insomnia 1, 4. The FDA label states it should be taken "preferably in the evening at bedtime" for depression, but this is for antidepressant dosing (15-45 mg), not hypnotic dosing 4.

Limited High-Quality Evidence

• The 2017 AASM guideline did not evaluate mirtazapine in their systematic review 2
• The 2008 AASM guideline notes "evidence for their efficacy when used alone is relatively weak" for sedating antidepressants 1
• Most recent positive data comes from small studies: 53 veterans 5, 60 older adults 7, and 19 healthy volunteers 6

Significant Adverse Effects

Common side effects that limit use 4:

• Weight gain: 7.5% gained ≥7% body weight in controlled trials (vs 0% placebo) 4
• Increased appetite: 17% vs 2% placebo 4
• Somnolence: 54% vs 18% placebo; led to discontinuation in 10.4% 4
• Next-day sedation: Documented in multiple studies 7, 6

Serious but rare risks 4:

• Low white blood cell count (agranulocytosis)
• Serotonin syndrome (especially with other serotonergic drugs)
• QT prolongation and cardiac arrhythmias
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
• Hyponatremia (particularly in elderly)
• Activation of mania/hypomania

When Mirtazapine May Be Appropriate

Consider mirtazapine specifically when 1, 8:

1. Comorbid major depression: Insomnia affects 75% of depressed patients; mirtazapine treats both conditions 8
2. Comorbid anxiety: Dual benefit for anxiety and sleep
3. Underweight patients: Weight gain becomes therapeutic rather than adverse
4. Substance abuse history: Non-scheduled medication preferred
5. Multiple failed trials: After BzRAs and ramelteon have failed

Avoid mirtazapine in 4:

• Patients concerned about weight gain
• Those with cardiovascular disease or QT prolongation risk
• Patients taking other serotonergic medications (SSRI, SNRI, MAOIs)
• Those requiring daytime alertness for safety-sensitive activities
• Patients with bipolar disorder (unless mood-stabilized)

Practical Prescribing Considerations

If prescribing mirtazapine for insomnia 4, 7, 6:

• Start with 7.5 mg at bedtime (half of a 15 mg tablet)
• Some clinicians use 3.75 mg for ultra-low dosing
• Take 30-60 minutes before desired sleep time
• Avoid alcohol and benzodiazepines 4
• Monitor for next-day sedation, weight gain, and mood changes
• Reassess after 2-4 weeks
• Do not abruptly discontinue: Taper gradually to avoid withdrawal symptoms 4

Patient counseling points 4:

• Expect increased appetite and possible weight gain
• May cause significant drowsiness the next day
• Avoid driving or operating machinery until effects are known
• Report fever, sore throat, or flu-like symptoms immediately (agranulocytosis warning)
• Not recommended in pregnancy or breastfeeding

The Bottom Line

While recent small studies show mirtazapine can improve insomnia symptoms 5, 7, 6, 8, major sleep medicine guidelines do not recommend it as a primary treatment for insomnia 1, 2. The 2017 AASM guideline suggests against trazodone (another sedating antidepressant) 2, and the 2020 VA/DoD guideline advises against trazodone specifically 3.

Reserve mirtazapine for patients with comorbid depression/anxiety or those who have failed FDA-approved hypnotics, understanding that you are using it off-label with limited evidence and significant side effect burden. The weight gain and next-day sedation are particularly problematic for many patients. When insomnia is the primary complaint without psychiatric comorbidity, stick with FDA-approved options that have stronger evidence and better safety profiles.